Evommune EVMN Ratios (2024-2026)

NYSE EVMN
$8.31 -0.08 (-0.95%)
As of: Sep 29, 2026 · 3:59 PM EDT
Reported Financials

Evommune Quarterly Ratios

Periods 7 quarters
Latest Jun 2026

Evommune ratios data for the quarter ended Jun 2026. These financial ratios cover 7 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin -480.63%-124.66%
EBIT Margin -501.07%-133.28%
EBITDA Margin -488.50%-130.17%
Operating Margin -501.07%-133.28%
Net Margin -485.23%-124.75%
FCF Margin -796.63%-97.66%
Efficiency
Assets AverageAssets Avg. 154.75M273.70M312.20M
Equity AverageEquity Avg. -133.38M-151.24M-164.74M-177.19M11.21M255.06M291.07M
Asset Utilization RatioAsset Util. 0.080.040.03
Valuation
Price to SalesP/S 8.0882.8148.22
Price to BookP/B 0.512.721.74
Enterprise Value -44.14M616.60M281.39M
Market Capitalization 105.06M828.06M482.18M
Return Ratios
Return on Sales [ROS]ROS -501.07%-133.28%-623.62%-899.92%-1,018.93%
Return on Capital Employed [ROCE]ROCE -59.25%-34.20%-34.57%
Return on Assets [ROA]ROA -50.24%-31.06%-30.32%
Return on Equity [ROE]ROE -693.29%-33.33%-32.52%

Evommune Ratios API

Pull Evommune's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=EVMN&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY